SYSTEMATIC REVIEW article

Front. Neurol., 25 March 2024

Sec. Neurological Biomarkers

Volume 15 - 2024 | https://doi.org/10.3389/fneur.2024.1351925

Elevated troponin levels as a predictor of mortality in patients with acute stroke: a systematic review and meta-analysis

  • Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India

Abstract

Background and Aim:

The prognostic potential of cardiac troponin (cTn) in acute stroke patients has been a subject of ongoing debate. Our objective was to provide a comprehensive evidence for predicting mortality in acute stroke patients by using the elevated troponin levels.

Methods:

We conducted an extensive literature search, including PubMed, EMbase, and Trip Databases, covering studies published up to September 30, 2023. We computed risk ratios (RR) with 95% confidence intervals (CIs), performed sensitivity analysis, and conducted trial sequential analysis (TSA).

Results:

In total, 53 studies were analyzed, with 37 focusing on acute ischemic stroke (AIS), 11 on subarachnoid hemorrhage (SAH), and 7 on Intracerebral hemorrhage (ICH). Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RR=3.80, 95% CI; 2.82 to 5.12) as well as SAH (RR=2.23, 95% CI; 1.64 to 3.02). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RR=1.13, 95% CI: 0.46 to 2.79). A similar pattern was observed for elevated cTn levels, indicating an increased risk of last follow-up mortality for AIS (RR=2.41, 95% CI: 1.98 to 2.93) and SAH (RR=3.08, 95% CI: 2.25 to 4.21).

Conclusion:

Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.

Introduction

Acute stroke represents a critical medical condition with substantial implications for patient outcomes and healthcare systems (1). In this context, the timely and accurate identification of prognostic markers capable of predicting stroke-associated mortality emerges as a paramount imperative (2). Such markers not only facilitate risk assessment but also guide precise and targeted clinical interventions, ultimately influencing patient outcomes and optimizing healthcare resource allocation (3). Cardiac Troponin (cTn), widely recognized as a cardinal biomarker in cardiology, has recently attracted attention for its potential role as an indicator of mortality risk in patients afflicted by acute stroke (4).

In the short term, the immediate post-stroke period, in-hospital mortality rates for acute stroke patients can exhibit alarming elevations, with figures occasionally reaching a staggering 50% (5). The major driving force behind such acute fatalities often lies in cardiac-related complications. These complications manifest through the release of cardiac troponin-T (cTnT), cardiac troponin-I (cTnI), High-sensitive cardiac Troponin I (hs-cTnI) and High-sensitive cardiac Troponin T (hs-cTnT) proteins into the circulatory system. Importantly, during the acute phase of ischemic stroke (IS), a marked elevation in serum levels of cTnT or cTnI is frequently observed, establishing a robust link between cardiac injury and the stroke itself (6). The precise and timely prognosis of this cardiac involvement not only impacts therapeutic strategies but also plays a pivotal role in the monitoring and management of patient outcomes, fundamentally shaping the quality of healthcare delivery (7).

However, despite the potential of cardiac troponin as a prognostic marker, the scientific literature presents contrasting findings regarding its association with the risk of all-cause mortality in patients afflicted with acute stroke (8). Moreover, the precision of risk estimates demonstrates considerable variability across individual research studies. Troponin elevations have been reported in a substantial proportion of stroke patients, with prevalence rates ranging from 27% to 34% (9). These elevations have been consistently linked to heightened mortality in various stroke subtypes, encompassing IS, Intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). Nevertheless, previous meta-analyses (6, 10–17) have failed to definitively establish troponin elevation as an independent and unequivocal prognostic factor in the context of acute stroke patients. As a result, the debate concerning the predictive utility of elevated cardiac troponin levels in the stroke population continues to be a subject of scientific scrutiny. Therefore, we aimed to conduct a systematic review and meta-analysis, aptly named ā€œElevated Troponin Levels as a Mortality Predictor in Acute Stroke,ā€ in order to explore the utility of cTn in predicting mortality following acute stroke.

Methods

Search strategy

The Cochrane Handbook (version 5.1.0) was used to conduct a systematic review and meta-analysis (18). The preferred reporting items for systematic reviews and meta-analyses (PRISMA) were followed throughout the systematic review’s creation (19). Electronic searches were conducted in databases including PubMed, EMbase, and Trip Databases up to 30th September 2023. Additionally, the reference list of retrieved studies and previous meta-analyses, was manually search for collecting more relevant studies often missed while performing the electronic search. The search aimed to identify studies the prediction of cTn level with the mortality rate in patient with acute stroke. The search utilized a set of specific keywords, including (ā€œTroponinā€ OR ā€œCardiac Troponinā€ OR ā€œcTnTā€ OR ā€œcTnIā€ OR ā€œTroponin Iā€ OR ā€œTroponin Tā€ OR ā€œHigh Sensitive Troponinā€ OR ā€œHigh Sensitive Troponin Iā€ OR ā€œhTnIā€ OR ā€œHigh Sensitive Troponin Tā€ OR ā€œhTnTā€) AND (ā€œStrokeā€ OR ā€œBrain Strokeā€ OR ā€œAcute Strokeā€ OR ā€œIschemic Strokeā€ OR ā€œCerebral Infarctionā€ OR ā€œIntracerebral Hemorrhageā€ OR ā€œHemorrhagic Strokeā€ OR ā€œSubarachnoid Hemorrhageā€ OR ā€œAneurysmal Subarachnoid Hemorrhageā€) AND (ā€œMortalityā€ OR ā€œMortality Rateā€ OR ā€œDeathā€ OR ā€œDeath Rateā€ OR ā€œPrognosisā€ OR ā€œOutcomeā€).

Selection criteria

Inclusion Criteria:
  • Published observational studies, including prospective cohort and retrospective cohort studies that investigate the predictive utility of Cardiac Troponin (cTn) as a biomarker for mortality in patients with acute stroke.

  • Studies that report data related to either in-hospital mortality and/or last follow-up mortality as endpoints.

  • Studies that provide data on cTn assay results at least for a single time point during the course of the study.

  • Studies involving human participants.

Exclusion Criteria:
  • Case reports, case series, review articles, gray literature, and editorials.

  • Studies not reporting relevant outcomes.

  • Unavailability of full-texts.

Data extraction

Two independent authors (ā€œAā€ and ā€œMSā€) conducted a meticulous evaluation of the identified articles to assess their eligibility for inclusion in our study. Upon the initial screening, the authors proceeded to a comprehensive examination of the full-text articles to validate their eligibility and to systematically extract relevant data. To facilitate this process, a standardized data extraction form was utilized, ensuring uniformity and thoroughness in data collection process. The following data was extracted from studies: First Author’s Name, Published year, Country, Study design, Study period, Sample size of elevated cTn and normal cTn groups, source, cTn cut-off value, cTn assessment time point, cTn type, cTn estimation method, In-hospital mortality, Last follow-up mortality outcome measured. The values of cTn levels were reported with different units in the included studies and were converted to similar units for analysis purpose using online unit conversion tools.1,2 Any disagreement were resolved through discussion with the corresponding author.

Quality assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) for observational cohort studies (20). The NOS evaluates study quality across three domains: selection of participants, comparability of groups, and ascertainment of outcomes. Studies were assigned scores ranging from 0 to 9, with higher scores indicating higher quality. Any discrepancies in quality scores were resolved through consensus with the corresponding author.

Publication bias

To assess publication bias, we employed a funnel plot analysis (21). Egger’s regression test was used to ascertain the asymmetry of funnel plots (22).

Statistical analysis

A fixed/random-effects model was used to calculate the pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was calculated with the I2 statistic. The heterogeneity was considered as significant in case of I2 more than 50% for which random effects model was applied, on the other hand, if I2 was less than 50%, then fixed-effect model was applied. Sensitivity analysis was performed by sequentially omitting a single study in each turn, to validate the pooled observed effect. In order to ascertain the sufficiency of our sample size and the statistical power of our meta-analysis, we conducted Trial Sequential Analysis (TSA). Tests were considered statistically significant at a p-value less than 0.05. All statistical analyses were carried out using STATA, version 12.0 (Stata Statistical Software, Release 12; StataCorp LP, College Station, TX).

Results

Search results and study characteristics

Figure 1 illustrates the PRISMA flow diagram detailing the inclusion and exclusion criteria for studies in our systematic review and meta-analysis. Initially, 1,234 studies were identified across three databases and from other sources. After removing duplicates, 237 articles remained, and following further exclusions, 62 full-text articles were assessed for eligibility. Finally, 53 studies (23–73) were included that examined the role of elevated troponin for predicting mortality in acute stroke. Among these studies, 37 studies focused on AIS patients (23–59), 11 on SAH patients (28, 53, 60–68), and 7 on ICH patients (28, 53, 69–73). The AIS studies involved 3,606 patients with elevated troponin and 14,099 patients with normal troponin, the SAH studies involved 450 patients with elevated troponin and 980 patients with normal troponin, and the ICH studies involved 1,041 patients with elevated troponin and 1,259 patients with normal troponin. Geographically, 24 AIS studies were conducted in Caucasian regions (23–38, 41, 42, 44, 49, 50, 53, 55, 56), and 13 in Asian regions (39, 40, 43, 45–48, 51, 52, 54, 57–59). For SAH, 10 studies were in Caucasian regions (28, 53, 60–66, 68), with only 1 in an Asian region (67). In ICH, 4 studies were in Caucasian regions (28, 53, 69, 72), and 3 in Asian regions (70, 71, 73). Two studies (28, 53) were common for AIS, SAH, and ICH subjects. The publication years ranged from 2000 to 2023, and the sample sizes varied from 43 to 1,718, with detailed baseline characteristics provided in Table 1.

Figure 1

Table 1

S. no.ReferencesCountryStudy designStudy periodETP(n)NTP (n)Cutoff valuecTn assessment timepointType of cTnEstimation methodSourceLast follow-up durationOutcome measured
Acute ischemic stroke
1.James et al. (23)New ZealandPCSJuly 1997–March 199830151>0.1 ug/lWithin 72 h of symptomcTnTELISASerumNRTroponin, mortality
2.Trooyen et al. (24)NorwayPCSJanuary 1999–June 199940109>0.4 μg/LWithin 48 h of symptomcTnIMEIASerumNRNeurological outcomes, mortality
3.Angelontanio et al. (25)ItalyPCSFebruary 2001–January 200218277>0.01 ng/mLWithin 24 h of symptomcTnIRIANRNRMortality, non-fatal MI event, non-fatal cardiopulmonary event
4.Barber et al. (26)UKPCSNR45177>0.2 μg/LWithin 24 h of symptomcTnICIASerum30 daysDeath or dependency (Rankin > 2)
5.Jensen et al. (27)DenmarkPCSAugust 2003–October 200425219>0.03 μg/LWithin 7 days after symptomhs-cTnTELISANR19 monthsAll-cause in-hospital mortality
6.Sandhu et al. (28)USAPCSNR23138>0.4 ng/mLWithin 24 h of symptomcTnINRSerumNRIn-hospital mortality
7.Hajdinjak et al. (29)SloveniaPCSJune 2006–May 20101690>0.04 μg/LWithin 24 h of symptomcTnTELISANRNRIn-hospital mortality
8.Scheitz et al. (30)GermanyRCSOctober 2009–October 2010103612>0.03 μg/LWithin 7 days after symptomcTnIELISANRNRUnfavorable outcome, Major neurologic improvement, In-hospital mortality
9.Jensen et al. (31)USAPCSAugust 2003–October 200465128>14 ng/LWithin 24 h of symptomhs-cTnTCIANR4.4 yearsAll-cause mortality
10.Boire et al. (32)CanadaPCSOctober 2006–November 201046362>0.03 ug/LWithin 72 h of symptomcTnINRNR90 daysDeath, myocardial Infarction, mRS score, recurrent stroke
11.Stahrenberg et al. (33)GermanyPCSMarch 2009–February 20109899≄6.15 pg./mLWithin 24 h of symptomhs-cTnTELISAPlasma12 monthsVascular events, all-cause mortality
12.Scheitz et al. (34)GermanyPCSFebruary 2011–Feb ruary2013308409>14 ng/LWithin 48 h of symptomcTnTELISANRNRUnfavorable neurological outcome and in-hospital mortality
13.Lasek-Bal et al. (35)PolandPCS2013–2014104964> 0.014 ng/mLWithin 72 h of symptomcTnIELISASerum30 daysMortality, mRS 4–6
14.Faiz et al. (36)NorwayRCSJune 2009–May 2010156131>14 ng/Lwithin 24 h of symptomhs-cTnTELISASerumNRIn-hospital mortality
15.Raza et al. (37)USARCS2008–201017183>0.40 ng/mLWithin 24 h of symptomcTnICIASerum2 yearsLong term cardiac adverse event, all cause death
16.Batal et al. (38)USAPCSDecember 2008–November 20103091,409>0.1 μg/LWithin 24 h of symptomcTnICIASerum3 yearsMortality
17.Maoz et al. (39)IsraelRCS1 year35177>0.03 μg/LNRhs-cTnTNRSerumNRNIHSS and mortality
18.Su et al. (40)TaiwanRCSAugust 2010–March 2015146725>0.01 μg/LWithin 48 h of symptomcTnIELISASerumNRpoor outcome and in-hospital mortality
19.Budincevic et al. (41)CroatiaRCS2007–201010188>0.5 ug/LWithin 24 h of symptomcTnINRNRNRUnfavorable outcome, death
20.Peddada et al. (42)USARCSMay 2008–December 2012199946>0.120 ng/mLWithin 7 days after symptomcTnICIASerumNRNIHSS and mortality
21.Akpinar et al. (43)TurkeyRCSNR1153>0.014 ng/mLWithin 48 h of symptomcTnTCIASerumMean: 9.6 daysIn-hospital mortality
22.Wrigley et al. (44)USARCS20102951,082between 40 and 50 ng/LWithin 24 h of symptomcTnT and cTnINRSerum3 YearLong-term mortality, Structural cardiac disease
23.Ahn et al. (45)KoreaRCSMay 2007–December 20141661,526>0.04 ng/mLWithin 48 h of symptomcTnICMIASerum33 monthsLong-term mortality
24.Fathy et al. (46)EgyptPCSMarch 2016–December 20161460>0.01 μg/L.Within 48 hcTnIELISASerumNRPoor short-term outcome and in-hospital mortality
25.He L. et al. (47)ChinaRCSMay 2012–December 2017118398≄14 ng/LWithin 72 hhs-cTnTCIASerum3 monthsDeath, Major disability
26.Ahn et al. (48)KoreaPCS2013–2015145947≄0.040 ng/mLWithin 48 hcTnICIASerum18 monthsAdverse long-term outcomes, mortality
27.He M. et al. (49)USARCSJanuary 2013–December 201625580.6 ng/mLWithin 48 hcTnNRNR1 yearAll-cause mortality, AMI, AIS, and all-cause re-hospitalization
28.Terceno et al. (50)SpainPCSNR4268≄14 ng/LWithin 24 h of symptomhs-cTnTNRPlasma3 monthsMortality, mRS, NIHSS
29.Sui et al. (51)ChinaPCSJanuary 2017–February 201865176>14 ng/LWithin 24 h of symptomhs-cTnTNRSerum90 daysMortality, disability
30.Cao et al. (52)ChinaRCSJanuary 2015–November 20178558>14 ng/LWithin 48 h of symptomhs-cTnTCIASerum3 monthsPoor outcome and mortality
31.Alkhachroum et al. (53)USARCSJanuary 2013–April 2015197621>0.04 ng/mLWithin 48 h of symptomcTnINRSerumNRDisease severity, mortality, functional outcome and discharge disposition
32.Thapa et al. (54)NepalPCSNR893> 0.034 ng/mLWithin 48 h of symptomhs-cTnICIASerumNRPoor outcomes and in-hospital mortality
33.Scheitz et al. (55)GermanyPCSJanuary 2010–June 2013220342>14 ng/LWithin 7 days of symptomhs-cTnTCIASerum3 yearRecurrent stroke, myocardial infarction, and all-cause death
34.Nageeb et al. (56)EgyptPCSJanuary 2017–January 20191359≄0.01 μg/LWithin 24 h after onsetcTnIELISASerum3 monthsDeath, disability, neurological improvement
35.Miraj et al. (57)BangladeshPCSNR892>0.04 ng/mLWithin 7 days after symptomcTnINRSerumNRPoor outcome and in-hospital mortality
36.Chen et al. (58)ChinaPCSFebruary 2016–November 202090264>0.03ug/Lwithin 24 h after onseths-cTnICIANR90 dayshscTnI, mortality
37.Kim et al. (59)KoreaRCSAugust 2014–July 201731170820.7 ng/L for men and 16.1 ng/L for womenwithin 24 h of symptomhs-cTnICIANR22.5 monthsMortality and cardiac and cerebrovascular events
Subarachnoid hemorrhage
38.Deibert et al. (60)USAPCSJanuary 1998–August 20001231≄1.4 ug/LOn admissioncTnINRSerumNRHome, acute rehabilitation, nursing home and death
39.Naidech et al. (61)USAPCSNovember 1998–October 20024681>0 to 0.5 ug/LOn admissioncTnINRSerum3 monthsFunctional disability or death
40.Sandhu et al. (28)USAPCSNR2076>0.4 ng/mLOn admissioncTnINRSerumNRIn-hospital mortality
41.Ramappa et al. (62)USAPCSJanuary 1999–December 20033152≄2.0 ng/mLOn admissioncTnINRSerumNRWorse neurological outcome and in-hospital mortality
42.Gupte et al. (63)USARCSAugust 2006–June 200947157>0.5 ng/mLOn admissioncTnINRNRNRIn-hospital mortality
43.Duello et al. (64)USARCSMarch 2011–July 201336139>0.10 ng/mLOn admissioncTnTNRNR1 monthMortality
44.Guette et al. (65)FrancePCSOctober 2012–August 20157661>22 ng/Lwithin 72 h of symptom onseths-cTnTELISAPlasma3 monthsSensitivity and specificity with corresponding 95% CIs.
45.Alkhachroum et al. (53)USARCSJanuary 2013–April 20154875>0.04 ng/mLOn admissioncTnINRSerumNRDisease severity, Mortality, functional outcome and discharge disposition
46.Akkermans et al. (66)NetherlandPCSNovember 2005–February 200843116>12 ng/LNRcTnINRSerum1 yearMyocardial infarction, cardiac death, all-cause mortality
47.Lin et al. (67)ChinaPCSJanuary 2016–December 201755158>0.016 ng/mLOn admissioncTnINRNR34.3 monthsMajor adverse cardiac events, long-term neurological outcomes, and mortality
48.Anetsberger et al. (68)GermanyPCSMarch 2013–December 20153634>0.007 μg/LOn admissioncTnTELISANR3 monthsFunctional outcome and mortality
Intracerebral hemorrhage
49.Hays et al. (69)USARCSJanuary 2001–January 20053884>0.10 ng/mLwithin 24 hcTnIRIASerumNRIn-hospital mortality
50.Sandhu et al. (28)USAPCSNR1480>0.4 ng/mLwithin 24 hcTnINRSerumNRIn-hospital mortality
51.Chung et al. (70)South KoreaRCSJanuary 2003–December 200728225>0.01 ng/mLWithin 24 admission hourscTnTELISASerumNRIn-hospital mortality
52.Xu et al. (71)ChinaRCSNR66122NRNRcTnINRNRNRIn-hospital mortality, GCS < 8, NIHSS >10
53.Gerner et al. (72)GermanyPCS2006–201483437>0.040 ng/mLWithin 72 h after admissioncTnICIAPlasmaNRFunctional outcome
54.He et al. (73)ChinaRCSJune 2012–December 201572988≄0.028 ng/mLNRcTnICIASerumNRIn-hospital mortality and mRS
55.Alkhachroum et al. (53)USARCSJanuary 2013–April 201583223>0.04 ng/mLOn admissioncTnINRSerumNRDisease severity, mortality, functional outcome and discharge disposition

Baseline characteristics for the included studies investigating for elevated Troponin level in predicting mortality for acute stroke patients.

RCS, Retrospective Cohort Study; PCS, Prospective Cohort Study; cTnI, Cardiac troponin I; cTnT, Cardiac troponin T; hs-cTnT, High-sensitive cardiac Troponin T; hs-cTnI, High-sensitive cardiac Troponin I; NIHSS, National Institute of Health Stroke Scale; GCS, Glasgow Coma Scale; mRS, Modified Rankin Scale; NR, not reported; ELISA, enzyme-linked immunosorbent assay; CIA, chemiluminescence immunoassay; RIA, radioimmunoassay; MEIA, Microparticle Enzyme Immunoassay; CMIA, chemiluminescent microparticle immunoassay.

Regarding predictive mortality outcomes, 15 studies with AIS patients (23–25, 28–30, 34, 36, 39–43, 54, 57), 6 with SAH (28, 53, 60, 62, 63, 67), and 7 with ICH (28, 53, 69–73) reported data for In-hospital mortality. For last follow-up mortality, 22 AIS studies (26, 27, 31–35, 37, 38, 44–53, 56, 58, 59) and 6 SAH studies (61, 64–68) provided relevant data. Only a single study (67) reported data both In-hospital mortality and last follow-up mortality for SAH subjects. The majority of studies included in our review received high ratings on the NOS Scale, indicating strong methodological quality (Table 2). Each study’s total score, ranging from 6 to 9, reflects its overall quality, supporting the reliability and validity of the evidence presented in this review.

Table 2

SelectionComparabilityOutcomeResult
S. no.ReferencesRepresentative of the exposed cohortSelection of the non-exposed cohortAscertainment of exposureDemonstration that outcome was not present at study startComparability of cohorts based on design or analysisAssessment of outcomeEnough follow up periodAdequacy of follow upTotal score
Acute ischemic stroke
1.James et al. (23)11111117
2.Trooyen et al. (24)1111116
3.Angelontanio et al. (25)111121119
4.Barber et al. (26)111121119
5.Jensen et al. (27)111121119
6.Sandhu et al. (28)1111116
7.Hajdinjak et al. (29)1111217
8.Scheitz et al. (30)1111217
9.Jensen et al. (31)11112118
10.Boire et al. (32)111121119
11.Stahrenberg et al. (33)111121119
12.Scheitz et al. (34)1111217
13.Lasek-Bal et al. (35)1111116
14.Faiz et al. (36)1111217
15.Raza et al. (37)111121119
16.Batal et al. (38)11112118
17.Maoz et al. (39)1111217
18.Su et al. (40)1111217
19.Budincevic et al. (41)1111116
20.Peddada et al. (42)1111217
21.Akpinar et al. (43)11111117
22.Wrigley et al. (44)1111217
23.Ahn et al. (45)111121119
24.Fathy et al. (46)1111217
25.He L. et al. (47)11112118
26.Ahn et al. (48)1112117
27.He M. et al. (49)111121119
28.Terceno et al. (50)111121119
29.Sui et al. (51)111121119
30.Cao et al. (52)111121119
31.Alkhachroum et al. (53)1111217
32.Thapa et al. (54)1111217
33.Scheitz et al. (55)111121119
34.Nageeb et al. (56)111121119
35.Miraj et al. (57)1111116
36.Chen et al. (58)111121119
37.Kim et al. (59)111121119
Subarachnoid hemorrhage
38.Deibert et al. (60)111111118
39.Naidech et al. (61)11111117
40.Sandhu et al. (28)1111116
41.Ramappa et al. (62)111121118
42.Gupte et al. (63)1111217
43.Duello et al. (64)111121119
44.Guette et al. (65)111121119
45.Alkhachroum et al. (53)1111217
46.Akkermans et al. (66)111111118
47.Lin et al. (67)111121119
48.Anetsberger et al. (68)111121119
Intracerebral hemorrhage
49.Hays et al. (69)1111217
50.Sandhu et al. (28)1111116
51.Chung et al. (70)1111217
52.Xu et al. (71)111121119
53.Gerner et al. (72)111121119
54.He et al. (73)1111217
55.Alkhachroum et al. (53)1111217

Quality assessment of included studies based on Newcastle-Ottawa Scale (NOS).

In-hospital mortality

Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality in both AIS (RR = 3.80, 95% CI; 2.82 to 5.12; Figure 2A) as well as SAH (RR = 2.23, 95% CI; 1.64 to 3.02; Figure 2B). However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (RR = 1.13, 95% CI: 0.46 to 2.79; Figure 2C).

Figure 2

Further subgroup analysis based on type of cTn, study design, Troponin cut-off value, and estimation method of troponin showed diverse patterns. Specifically for AIS subgroup analysis based on type of troponin, cTnI had a higher prediction risk (RR: 3.93; 95% CI: 2.34 to 6.60) than cTnT (RR: 3.63; 95% CI: 2.24 to 5.88) and hs-cTnT (RR: 3.34; 95% CI: 1.32 to 8.47) while hscTnI had (RR: 6.40; 95% CI: 1.21 to 33.88; Supplementary Table S1A). Based on study design, prospective cohort studies (PCS) had a higher risk (RR: 4.00; 95% CI: 2.43 to 6.57) compared to retrospective cohort studies (RCS) [RR: 3.66; 95% CI: 2.45 to 5.47]. Troponin cut-off values also showed variation, with 0.01 to 0.05 μg/L at RR: 4.55 (95% CI: 3.29 to 6.29) and 0.1 to 0.5 μg/L at RR: 2.86 (95% CI: 1.70 to 4.83). Assessment time-points within 24, 48, and 72 h had different risks.

The choice of troponin estimation methods significantly influenced risk, with Enzyme-Linked Immunosorbent Assay (ELISA) resulting in RR: 3.56 (95% CI: 2.07 to 6.12), Radioimmunoassay (RIA) at RR: 4.57 (95% CI: 2.23 to 9.34), and chemiluminescence immunoassay (CIA) at RR: 2.92 (95% CI: 2.16 to 3.96). Prediction risks varied at assessment time-points within 24, 48, and 72 h, but stability was observed for studies examining troponin levels within 24 h after Acute Ischemic Stroke (AIS). For SAH patients, subgroup analysis for showed that cTnI had a higher predictive risk for In-hospital mortality (RR = 2.23; 95% CI: 1.64 to 3.02). Both PCS (RR = 2.31; 95% CI: 1.49 to 3.58) and RCS (RR = 2.15; 95% CI: 1.40 to 3.31) also showed higher predictive role of elevated troponin for the In-hospital mortality in SAH patients (Supplementary Table S1B). For ICH, subgroup analysis revealed non-significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients (Supplementary Table S1C). Only significant association for the assessment time point of troponin levels within 24 h and within 48 h after ICH (RR = 1.76; 95% CI: 1.01 to 3.06) and (RR = 3.05; 95% CI: 1.17 to 7.91) respectively were observed (Supplementary Table S1C).

Last follow-up mortality

Elevated cTn levels were also significantly showed a higher predictive risk for last follow-up mortality in both AIS (RR = 2.41, 95% CI: 1.98 to 2.93; Figure 3A) and SAH (RR = 3.08, 95% CI: 2.25 to 4.21; Figure 3B). Subgroup analysis showed hs-cTnT stood out with a significantly higher prediction risk (RR: 6.02; 95% CI: 2.60 to 13.93) in AIS, compared to cTnT and cTnI (Supplementary Table S2A). Both prospective and retrospective study designs, indicated an elevated predictive role of elevated troponin for last follow-up mortality in AIS and SAH subgroup analysis (Supplementary Tables S2A,B). Predictive risk remained stable for studies examining troponin levels within 24 h after AIS and SAH. Troponin estimation methods varied for AIS studies, with most utilizing CIA method, while for SAH, the predominant method was ELISA. Analysis on last follow-up mortality in ICH group was not feasible as only a single study provided data for it.

Figure 3

Publication bias

Funnel plot analysis did not reveal any apparent signs of asymmetry. The distribution of studies around the estimated effect appeared to be even, suggesting the absence of significant publication bias that could impact the results. Funnel plots for the in-hospital mortality in patients with AIS (p = 0.45), SAH (p = 0.10), and ICH (p = 0.19), and last follow-up mortality for AIS (p = 0.13), and SAH (p = 0.42), are represented in Supplementary Figures S1A–C, S2A,B.

Sensitivity analysis

Sensitivity analysis indicated that the pooled risk estimates for in-hospital mortality in patients with AIS, SAH, and ICH was not significantly affected by the removal of any individual study (Supplementary Figures S3A–C). Similarly, the pooled risk estimates for last follow-up mortality in patients with AIS and SAH was not significantly affected by the removal of any individual study (Supplementary Figures S4A,B). Our findings suggest that the results of the meta-analysis are robust and are not driven by any single study which provides additional confidence in the validity of the findings.

Trial sequential analysis

Our Trial sequential analysis (TSA) showed a very promising strength with 77% power with total sample size of 4,939 AIS patients and 55% power for the studies with 3,062 HS subjects. TSA plot are represented in Figures 4A,B. The high power of the TSA suggests that the meta-analysis is unlikely to be influenced by chance or random fluctuations in the data. Overall, the TSA results provide strong evidence that the meta-analysis is well-powered and that the findings are reliable and generalizable. This reinforces the importance of considering troponin elevation as a crucial factor in risk stratification and treatment decisions for patients with acute stroke.

Figure 4

Discussion

Our findings highlights the significance of routinely assessing admission cTn in stroke patients, emphasizing its association with higher mortality rates. Existing literature has consistently reported the association between elevated troponin levels and all-cause mortality across various stroke types (10, 12). Studies have shown that baseline troponin levels predict poor outcomes in both in-hospital and last follow-up scenarios, irrespective of acute coronary syndrome (69, 71, 72). Furthermore, higher blood troponin levels during the acute phase of acute spontaneous ICH are linked with unfavorable outcomes (69, 71, 72). Similar findings are observed in patients with spontaneous subarachnoid hemorrhage, where an increased risk of cerebral ischemia and death is demonstrated (13, 14, 60).

The current meta-analysis supports and reinforces these findings, indicating that elevated troponin levels serve as predictors for both in-hospital and follow-up mortalities for AIS with additional finding of other subtypes of stroke including SAH and ICH. Elevated cTn levels were significantly showed a higher predictive risk for In-hospital mortality and last follow-up mortality in both AIS as well as SAH. However, no significant predictive risk between elevated cTn levels and in-hospital mortality for ICH patients. However, it’s crucial to note that this observation may be influenced by the limited inclusion of only seven studies in the overall analysis.

Previous findings have reported that elevation of cardiac troponin has been reported to occur in ICH patients along with only 1.2% of them died of cardiac causes (69). Although previous studies have been tried to address hypothesis that elevated cardiac troponin might serve as prognostic markers for prediction of adverse clinical events, the results were largely inconsistent and inconclusive with regard to ICH. The previous study demonstrated that elevated troponin levels were associated with higher mortality following ICH (69). Subsequently, the utility of elevated troponin levels for prediction of mortality was confirmed in surgical ICH patients (74), but was not found to be consistently associated with in-hospital mortality in Chinese ICH patients (71). Small sample sizes (less than 240 stroke patients) and ethnic variability probably contribute to the negative results and discrepancies. Similarly in our meta-analysis, only seven ICH studies were included and we observed non-significant association with the elevated level of Troponin.

Approximately 18%–20% (75–77) of ischemic stroke patients present with elevated high-sensitive Troponin T (hsTnT) levels on admission, which can be attributed to various factors including renal failure, chronic heart failure, myocardial infarction (MI), and stress-related cardiomyopathies such as neurogenic stunned myocardium (NSM). NSM, characterized by contraction band necrosis at the cellular level, manifests with elevated hsTnT levels and electrocardiographic abnormalities (78–81). While some patients can be differentiated using ECG and echocardiography, overlap in diagnostic criteria complicates diagnosis for others. Despite common assumptions in stroke centers, attributing elevated hsTnT levels solely to brain or heart origin may not always hold true, as MI patients have an increased risk of stroke (82), even with marginally elevated hsTnT levels, raising questions about predictive value in differentiating NSM from MI (83).

As per the 2023 Guideline for the Management of Patients with SAH by AHA/ASA (84), certain medical parameters, such as BMI, hypertension, hyperglycemia, troponin levels, hyperthermia, peak white blood cell count, C-reactive protein, and high neutrophil counts, have been linked to clinical outcomes in SAH. However, it is emphasized that additional investigation is necessary to determine their prognostic value and influence on treatment outcomes. Furthermore, the guideline underscores the active exploration of novel biomarkers, encompassing imaging, serum, and cerebrospinal fluid (CSF), in the field of SAH. Ongoing research incorporating advanced proteomic, genomic, and other biological marker methods, in conjunction with existing clinical, radiographic, and physiological monitoring data, is deemed essential. These efforts aim to shed light on the potential use of biomarkers for prognosis and interventions, ultimately contributing to improved outcomes in patients with SAH.

The COVID-19 pandemic has placed unprecedented strain on stroke services globally, disrupting healthcare delivery and raising concerns about its impact on stroke outcomes (85). Despite these challenges, our meta-analysis did not identify any explicit instances linking the pandemic with influential impacts on stroke management or patient outcomes across included studies. This highlights the need for further research to understand the nuanced interplay between COVID-19 and stroke care delivery, while also emphasizing the importance of developing adaptive strategies and fostering interdisciplinary collaborations to mitigate the pandemic’s adverse effects on stroke services and ensure optimal patient care.

Clinical decision-making regarding troponin elevations in stroke patients is a multifaceted challenge that requires careful consideration of various factors. While elevated troponin levels in stroke patients can indicate myocardial injury, termed ā€œtroponitis,ā€ it’s essential to recognize that other contributing factors such as stress, sepsis, or renal dysfunction may also lead to troponin elevation, particularly in the acute phase of a stroke (86). Therefore, clinicians must conduct a thorough evaluation to differentiate between myocardial infarction and other causes of troponin elevation (87). This evaluation typically involves a comprehensive clinical assessment, including medical history, physical examination, electrocardiography, and imaging studies such as echocardiography or cardiac MRI (88).

Additionally, clinicians may utilize risk stratification tools or algorithms specific to stroke patients with troponin elevations to guide further diagnostic and therapeutic interventions. Collaboration between neurologists, cardiologists, and other specialists is crucial in developing a cohesive management plan tailored to the individual patient’s needs, balancing the risks and benefits of interventions such as antiplatelet therapy, anticoagulation, or coronary angiography (89). Ultimately, the decision-making process should prioritize patient safety, optimizing outcomes, and improving overall care in stroke units. Ongoing research and consensus guidelines from professional societies play a vital role in informing evidence-based practices and advancing our understanding of troponin elevations in stroke patients.

Study limitations

While the study has strengths, it acknowledges limitations, including: (1) using a single baseline cTn assessment time point and non-standardized measurement procedures, potentially introducing misclassification; (2) lacking information on important confounders like infarction locations, stroke severity, time from symptom onset, and type of recanalization therapies, which could bias the relationship between elevated cTn and mortality; (3) absence of data on functional outcomes like the modified Rankin Scale; and (4) variations in cut-off values, assay methods, and follow-up periods across individual studies contributed to high heterogeneity from pooled analysis by troponin assays, complicating result interpretation.

Conclusion

Elevated troponin levels can serve as a promising predictive marker for both in-hospital and last follow-up mortality in AIS and SAH patients but not in ICH patients. Further prospective studies are needed to validate our findings along with exploring the preventive management of mortality in acute stroke settings.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

AG: Writing – review & editing, Writing – original draft, Methodology, Data curation. MS: Investigation, Writing – review & editing, Methodology, Data curation, Project administration. PK: Writing – review & editing, Writing – original draft, Supervision, Software, Formal analysis, Conceptualization.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1351925/full#supplementary-material

References

  • 1.

    TadiPLuiF. Acute Stroke In: StatPearls. Treasure Island (FL): StatPearls Publishing (2023)

  • 2.

    Roman-FilipCCatanăM-GMihăilăR-G. Prognostic markers for ischemic stroke—are they truly reliable?Med Pharm Rep. (2023) 96:65–70. doi: 10.15386/mpr-2365

  • 3.

    SaceleanuVMToaderCPlesHCovache-BusuiocRACostinHPBratuBGet al. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. (2023) 11:2617. doi: 10.3390/biomedicines11102617

  • 4.

    WetterstenNMaiselA. Role of cardiac troponin levels in acute heart failure. Card Fail Rev. (2015) 1:102–6. doi: 10.15420/cfr.2015.1.2.102

  • 5.

    GrefkesCFinkGR. Recovery from stroke: current concepts and future perspectives. Neurol Res Pract. (2020) 2:17. doi: 10.1186/s42466-020-00060-6

  • 6.

    FanYJiangMGongDManCChenY. Cardiac troponin for predicting all-cause mortality in patients with acute ischemic stroke: a meta-analysis. Biosci Rep. (2018) 38:BSR20171178. doi: 10.1042/BSR20171178

  • 7.

    BohrAMemarzadehK. The rise of artificial intelligence in healthcare applications. Artif Intell Healthc. (2020) 25–60:2. doi: 10.1016/B978-0-12-818438-7.00002-2

  • 8.

    AbdiSOveis-GharanSSinaeiFGhorbaniA. Elevated troponin T after acute ischemic stroke: association with severity and location of infarction. Iran J Neurol. (2015) 14:35–40. PMID:

  • 9.

    EtgenTBaumHSanderKSanderD. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke. (2005) 36:270–5. doi: 10.1161/01.STR.0000151364.19066.a1

  • 10.

    AlhazzaniAKumarAAlgahtanyMRawatD. Role of troponin as a biomarker for predicting outcome after ischemic stroke. Brain Circ. (2021) 7:77–84. doi: 10.4103/bc.bc_51_20

  • 11.

    BroersenLHAStenglHNolteCHWestermannDEndresMSiegerinkBet al. Association between high-sensitivity cardiac troponin and risk of stroke in 96 702 individuals: a Meta-analysis. Stroke. (2020) 51:1085–93. doi: 10.1161/STROKEAHA.119.028323

  • 12.

    DousGVGrigosACGrodmanR. Elevated troponin in patients with acute stroke – is it a true heart attack?Egypt Heart J. (2017) 69:165–70. doi: 10.1016/j.ehj.2017.01.005

  • 13.

    Memar MontazerinSChiGMarandiRNajafiHShojaeiFLeeJJet al. Evaluation of cardiac troponin and adverse outcomes after aneurysmal subarachnoid hemorrhage: a systematic review and Meta-analysis. Neurocrit Care. (2022) 36:650–61. doi: 10.1007/s12028-021-01368-0

  • 14.

    ZhangLWangZQiS. Cardiac troponin elevation and outcome after subarachnoid hemorrhage: a systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2015) 24:2375–84. doi: 10.1016/j.jstrokecerebrovasdis.2015.06.030

  • 15.

    ZhangYOuyangMQiuJCaoXXuBSuiY. Prognostic value of serum cardiac troponin in acute ischemic stroke: an updated systematic review and Meta-analysis. J Stroke Cerebrovasc Dis. (2022) 31:106444. doi: 10.1016/j.jstrokecerebrovasdis.2022.106444

  • 16.

    LippiGCervellinGSanchis-GomarF. Predicting mortality with cardiac troponins: recent insights from meta-analyses. Diagnosi. (2021) 8:37–49. doi: 10.1515/dx-2019-0061

  • 17.

    PitliyaAAlEdaniEMBhanguJKJavedKManshahiaPKNaharSet al. The impact of elevated troponin levels on clinical outcomes in patients with acute ischemic stroke: a systematic review. Ann Indian Acad Neurol. (2023) 26:641–54. doi: 10.4103/aian.aian_567_23

  • 18.

    CumpstonMLiTPageMJChandlerJWelchVAHigginsJPet al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. (2019) 10:ED000142. doi: 10.1002/14651858.ED000142

  • 19.

    MoherDShamseerLClarkeMGhersiDLiberatiAPetticrewMet al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. (2015) 4:1. doi: 10.1186/2046-4053-4-1

  • 20.

    StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

  • 21.

    BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088–101. doi: 10.2307/2533446

  • 22.

    EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

  • 23.

    JamesP. Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ. (2000) 320:1502–4. doi: 10.1136/bmj.320.7248.1502

  • 24.

    TroĆøyenMIndredavikB. Myocardial damage in acute stroke assessed with troponin I. Tidsskr Nor Laegeforen. (2001) 121:421–5.

  • 25.

    Di AngelantonioE. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. (2005) 76:76–81. doi: 10.1136/jnnp.2004.041491

  • 26.

    BarberMMortonJJMacfarlanePWBarlowNRoditiGStottDJ. Elevated troponin levels are associated with Sympathoadrenal activation in acute Ischaemic stroke. Cerebrovasc Dis. (2007) 23:260–6. doi: 10.1159/000098325

  • 27.

    JensenJKKristensenSRBakSAtarDHĆøilund-CarlsenPFMickleyH. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. (2007) 99:108–12. doi: 10.1016/j.amjcard.2006.07.071

  • 28.

    SandhuRAronowWSRajdevASukhijaRAminHD'aquilaKet al. Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Am J Cardiol. (2008) 102:632–4. doi: 10.1016/j.amjcard.2008.04.036

  • 29.

    HajdinjakEKlemenPGrmecÅ . Prognostic value of a single prehospital measurement of N-terminal pro-brain natriuretic peptide and troponin T after acute Ischaemic stroke. J Int Med Res. (2012) 40:768–76. doi: 10.1177/147323001204000243

  • 30.

    ScheitzJFEndresMMochmannH-CAudebertHJNolteCH. Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. Int J Cardiol. (2012) 157:239–42. doi: 10.1016/j.ijcard.2012.01.055

  • 31.

    JensenJKUelandTAukrustPAntonsenLKristensenSRJanuzziJLet al. Highly sensitive troponin T in patients with acute ischemic stroke. Eur Neurol. (2012) 68:287–93. doi: 10.1159/000341340

  • 32.

    Beaulieu-BoireILeblancNBergerLBoulangerJ-M. Troponin elevation predicts atrial fibrillation in patients with stroke or transient ischemic attack. J Stroke Cerebrovasc Dis. (2013) 22:978–83. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.008

  • 33.

    StahrenbergRNiehausCFEdelmannFMendeMWohlfahrtJWasserKet al. High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia. J Neurol Neurosurg Psychiatry. (2013) 84:479–87. doi: 10.1136/jnnp-2012-303360

  • 34.

    ScheitzJFMochmannHCErdurHTütüncüSHaeuslerKGGrittnerUet al. Prognostic relevance of cardiac troponin T levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: analyses from the TRELAS cohort. Int J Cardiol. (2014) 177:886–93. doi: 10.1016/j.ijcard.2014.10.036

  • 35.

    Lasek-BalAKowalewska-TwardelaTGąsiorZWarsz-WianeckaAHaberkaMPuzPet al. The significance of troponin elevation for the clinical course and outcome of first-ever Ischaemic stroke. Cerebrovasc Dis. (2014) 38:212–8. doi: 10.1159/000365839

  • 36.

    FaizKWThommessenBEinvikGBrekkePHOmlandTRĆønningOM. Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke. BMC Neurol. (2014) 14:96. doi: 10.1186/1471-2377-14-96

  • 37.

    RazaFAlkhouliMSandhuPBhattRBoveAA. Elevated cardiac troponin in acute stroke without acute coronary syndrome predicts long-term adverse cardiovascular outcomes. Stroke Res Treat. (2014) 2014:1–6. doi: 10.1155/2014/621650

  • 38.

    BatalOJentzerJBalaneyBKoliaNHickeyGDardariZet al. The prognostic significance of troponin I elevation in acute ischemic stroke. J Crit Care. (2016) 31:41–7. doi: 10.1016/j.jcrc.2015.09.018

  • 39.

    MaozARosenbergSLekerRR. Increased high-sensitivity troponin-T levels are associated with mortality after ischemic stroke. J Mol Neurosci. (2015) 57:160–5. doi: 10.1007/s12031-015-0593-7

  • 40.

    SuY-CHuangK-FYangF-YLinS-K. Elevation of troponin I in acute ischemic stroke. PeerJ. (2016) 4:e1866. doi: 10.7717/peerj.1866

  • 41.

    BudincevicHSremecJCrnacPOstojicVGalicEBielenI. Impact of troponin I on outcome of ischemic stroke patients. Rom J Intern Med. (2017) 55:19–22. doi: 10.1515/rjim-2016-0044

  • 42.

    PeddadaKCruz-FloresSGoldsteinLBFeenEKennedyKFHeuringTet al. Ischemic stroke with troponin elevation: patient characteristics, resource utilization, and in-hospital outcomes. Cerebrovasc Dis. (2016) 42:213–23. doi: 10.1159/000445526

  • 43.

    AkpinarO. Prognostic value of troponin t in patients with acute ischemic stroke in EMERGENCY department. Acta Medica Mediterr. (2017) 757–761:111. doi: 10.19193/0393-6384_2017_5_111

  • 44.

    WrigleyPKhouryJEckerleBAlwellKMoomawCJWooDet al. Prevalence of positive troponin and echocardiogram findings and association with mortality in acute ischemic stroke. Stroke. (2017) 48:1226–32. doi: 10.1161/STROKEAHA.116.014561

  • 45.

    AhnS-HLeeJSKimYHKimBJKimYJKangDWet al. Prognostic significance of troponin elevation for long-term mortality after ischemic stroke. J Stroke. (2017) 19:312–22. doi: 10.5853/jos.2016.01942

  • 46.

    FathyHAAshourWMRElserafyTSAmerMM. The prognostic value of elevated cardiac troponin-I in short-term outcome of acute ischemic stroke. Int J Clin Exp Neurol. (2018) 6:1–7.

  • 47.

    HeLWangJDongW. The clinical prognostic significance of hs-cTnT elevation in patients with acute ischemic stroke. BMC Neurol. (2018) 18:118. doi: 10.1186/s12883-018-1121-5

  • 48.

    AhnS-HKimYHLeeJSHanJHKimSYKangDWet al. Troponin I levels and long-term outcomes in acute ischemic stroke patients. J Am Coll Cardiol. (2019) 73:525–6. doi: 10.1016/j.jacc.2018.11.022

  • 49.

    HeMPanchangamSCruzBMukherjeeD. Underutilization of cardiac therapies in patients with acute ischemic stroke and elevated troponin. Cardiovasc Hematol Agents Med Chem. (2019) 17:144–51. doi: 10.2174/1871525717666191019115338

  • 50.

    TerceñoMSilvaYBashirSVera-MongeVBuxóMSerenaJ. Troponin T predicts Cardioembolic Aetiology and clinical outcome in undetermined Ischaemic stroke in Hyperacute phase. J Stroke Cerebrovasc Dis. (2020) 29:104528. doi: 10.1016/j.jstrokecerebrovasdis.2019.104528

  • 51.

    SuiYLiuTLuoJXuBZhengLZhaoWet al. Elevation of high-sensitivity cardiac troponin T at admission is associated with increased 3-month mortality in acute ischemic stroke patients treated with thrombolysis. Clin Cardiol. (2019) 42:881–8. doi: 10.1002/clc.23237

  • 52.

    CaoY-ZZhaoLBLiuSLiuQHJiangLZhouCGet al. Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with acute ischemic stroke treated with endovascular thrombectomy. J Clin Neurosci. (2019) 64:145–9. doi: 10.1016/j.jocn.2019.03.030

  • 53.

    AlkhachroumAMMillerBChamiTTatsuokaCSilaC. A troponin study on patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage: type II myocardial infarction is significantly associated with stroke severity, discharge disposition and mortality. J Clin Neurosci. (2019) 64:83–8. doi: 10.1016/j.jocn.2019.04.005

  • 54.

    ThapaPAgrawalJPBaniyaR. A study on elevation of troponin I in ischemic stroke as an independent prognostic marker of outcomes. Nepal J Neurosci. (2020) 17:26–34. doi: 10.3126/njn.v17i2.30224

  • 55.

    ScheitzJFStenglHNolteCHLandmesserUEndresM. Neurological update: use of cardiac troponin in patients with stroke. J Neurol. (2021) 268:2284–92. doi: 10.1007/s00415-020-10349-w

  • 56.

    NageebRSOmranAAMohamedWS. Troponin-I elevation predicts outcome after thrombolysis in ischemic stroke patients. Egypt J Neurol Psychiatry Neurosurg. (2021) 57:4. doi: 10.1186/s41983-020-00256-2

  • 57.

    MirajAAMohammadQDRahmanSMiahS. Elevation of troponin I in ischemic stroke of outcomes in patients with acute stroke. Acute Stroke Br J Res. (2022) 9:120. doi: 10.21767/2394-3718.9.12.120

  • 58.

    ChenFBaiXWangXZhangLWangFHuangLet al. Impact of high-sensitivity troponin elevation and dynamic changes on 90-day mortality in patients with acute ischemic stroke after mechanical thrombectomy: results from an observational cohort. J NeuroInterventional Surg. (2022) 15:1142–7. doi: 10.1136/jnis-2022-019682

  • 59.

    KimBSParkJJChangHKimSHKwonCHChungSMet al. Association of High-Sensitivity Troponin I with cardiac and cerebrovascular events in patient after ischemic stroke. Cerebrovasc Dis. (2023) 52:153–9. doi: 10.1159/000525920

  • 60.

    DeibertEBarzilaiBBravermanACEdwardsDFAiyagariVDaceyRet al. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. J Neurosurg. (2003) 98:741–6. doi: 10.3171/jns.2003.98.4.0741

  • 61.

    NaidechAMKreiterKTJanjuaNOstapkovichNDParraACommichauCet al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. (2005) 112:2851–6. doi: 10.1161/CIRCULATIONAHA.105.533620

  • 62.

    RamappaPThataiDCoplinWGellmanSCarhuapomaJRQuahRet al. Cardiac troponin-I: a predictor of prognosis in subarachnoid hemorrhage. Neurocrit Care. (2008) 8:398–403. doi: 10.1007/s12028-007-9038-7

  • 63.

    GupteMJohnSPrabhakaranSLeeVH. Troponin elevation in subarachnoid hemorrhage does not impact in-hospital mortality. Neurocrit Care. (2013) 18:368–73. doi: 10.1007/s12028-012-9813-y

  • 64.

    DuelloKMNagelJPThomasCSBlackshearJLFreemanWD. Relationship of troponin T and age- and sex-adjusted BNP elevation following subarachnoid hemorrhage with 30-day mortality. Neurocrit Care. (2015) 23:59–65. doi: 10.1007/s12028-014-0105-6

  • 65.

    GuettePLauneyYArnouatMBleichnerJPMasseretERousseauCet al. Prognostic value of high-sensitivity troponin T in aneurysmal subarachnoid hemorrhage: a prospective observational study. Brain Inj. (2019) 33:1372–8. doi: 10.1080/02699052.2019.1641742

  • 66.

    AkkermansAPeelenLMVan WaesJARinkelGJVan KleiWA. Cardiac events within one year after a subarachnoid haemorrhage: the predictive value of troponin elevation after aneurysm occlusion. Eur J Prev Cardiol. (2019) 26:420–8. doi: 10.1177/2047487318776098

  • 67.

    LinFChenYHeQZengCZhangCChenXet al. Prognostic value of elevated cardiac troponin I after aneurysmal subarachnoid hemorrhage. Front Neurol. (2021) 12:677961. doi: 10.3389/fneur.2021.677961

  • 68.

    AnetsbergerAJungwirthBBlobnerMRingelFBernlochnerIHeimMet al. Association of Troponin T levels and functional outcome 3 months after subarachnoid hemorrhage. Sci Rep. (2021) 11:16154. doi: 10.1038/s41598-021-95717-w

  • 69.

    HaysADiringerMN. Elevated troponin levels are CME associated with higher mortality following intracerebral hemorrhage. Neurology. (2006) 66:1330–4. doi: 10.1212/01.wnl.0000210523.22944.9b

  • 70.

    ChungP-WWonYSKwonYJChoiCSKimBM. Initial troponin level as a predictor of prognosis in patients with intracerebral hemorrhage. J Korean Neurosurg Soc. (2009) 45:355–9. doi: 10.3340/jkns.2009.45.6.355

  • 71.

    XuMLinJWangDLiuMHaoZLeiC. Cardiac troponin and cerebral herniation in acute intracerebral hemorrhage. Brain Behav. (2017) 7:e00697. doi: 10.1002/brb3.697

  • 72.

    GernerSTAuerbeckKSprügelMISembillJAMadžarDGƶlitzPet al. Peak troponin I levels are associated with functional outcome in intracerebral hemorrhage. Cerebrovasc Dis. (2018) 46:72–81. doi: 10.1159/000492395

  • 73.

    HeYLiuQWangJWangDWDingHWangW. Prognostic value of elevated cardiac troponin I in patients with intracerebral hemorrhage. Clin Cardiol. (2020) 43:338–45. doi: 10.1002/clc.23320

  • 74.

    GarrettMCKomotarRJStarkeRMDoshiDOttenMLConnollyES. Elevated troponin levels are predictive of mortality in surgical intracerebral hemorrhage patients. Neurocrit Care. (2010) 12:199–203. doi: 10.1007/s12028-009-9245-5

  • 75.

    AndersBAlonsoAArtemisDSchƤferAEbertAKablauMet al. What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients?Cerebrovasc Dis. (2013) 36:211–7. doi: 10.1159/000353875

  • 76.

    DarkiASchneckMJAgrawalARupaniABarronJT. Correlation of elevated troponin and echocardiography in acute ischemic stroke. J Stroke Cerebrovasc Dis. (2013) 22:959–61. doi: 10.1016/j.jstrokecerebrovasdis.2011.12.004

  • 77.

    KerrGRayGWuOStottDJLanghorneP. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis. (2009) 28:220–6. doi: 10.1159/000226773

  • 78.

    NguyenHZaroffJG. Neurogenic stunned myocardium. Curr Neurol Neurosci Rep. (2009) 9:486–91. doi: 10.1007/s11910-009-0071-0

  • 79.

    DombrowskiKLaskowitzD. Cardiovascular manifestations of neurologic disease. Handb Clin Neurol. (2014) 119:3–17. doi: 10.1016/B978-0-7020-4086-3.00001-1

  • 80.

    ApakIIltumurKTamamYKayaN. Serum cardiac troponin T levels as an indicator of myocardial injury in ischemic and hemorrhagic stroke patients. Tohoku J Exp Med. (2005) 205:93–101. doi: 10.1620/tjem.205.93

  • 81.

    MazzeoATMicalizziAMasciaLScicoloneASiracusanoL. Brain-heart crosstalk: the many faces of stress-related cardiomyopathy syndromes in anaesthesia and intensive care. Br J Anaesth. (2014) 112:803–15. doi: 10.1093/bja/aeu046

  • 82.

    VisserCAKanGLieKIDurrerD. Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. Eur Heart J. (1983) 4:333–7. doi: 10.1093/oxfordjournals.eurheartj.a061470

  • 83.

    HeldnerMRPilgrimTWustmannKHsiehKMattleHPArnoldMet al. Acute carotid T occlusion in a young patient: cryptogenic origin?Stroke. (2014) 45:e125–7. doi: 10.1161/STROKEAHA.114.005388

  • 84.

    HohBLKoNUAmin-HanjaniSChouSH-YCruz-FloresSDangayachNSet al. 2023 guideline for the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke. (2023) 54:e314–70. doi: 10.1161/STR.0000000000000436

  • 85.

    SmallCMehkriYPantherEFelismaPLucke-WoldB. Coronavirus Disease-2019 and stroke: pathophysiology and management. Can J Neurol Sci J Can Sci Neurol. (2023) 50:495–502. doi: 10.1017/cjn.2022.267

  • 86.

    van BeekDECvan der HorstICCScheerenTWL. Troponin elevations after cardiac surgery: just ā€œTroponitisā€? In: VincentJ-L, editor. Annual update in intensive care and Emergency medicine 2020. Cham: Springer International Publishing (2020). 113–24.

  • 87.

    BodyRCarltonE. Understanding cardiac troponin part 1: avoiding troponinitis. Emerg Med J EMJ. (2018) 35:120–5. doi: 10.1136/emermed-2017-206812

  • 88.

    KorffSKatusHAGiannitsisE. Differential diagnosis of elevated troponins. Heart. (2006) 92:987–93. doi: 10.1136/hrt.2005.071282

  • 89.

    AlaourBLiewFKaierTE. Cardiac troponin—diagnostic problems and impact on cardiovascular disease. Ann Med. (2018) 50:655–65. doi: 10.1080/07853890.2018.1530450

Summary

Keywords

troponin, mortality, acute stroke, ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage

Citation

Gulia A, Srivastava M and Kumar P (2024) Elevated troponin levels as a predictor of mortality in patients with acute stroke: a systematic review and meta-analysis. Front. Neurol. 15:1351925. doi: 10.3389/fneur.2024.1351925

Received

07 December 2023

Accepted

29 February 2024

Published

25 March 2024

Volume

15 - 2024

Edited by

Faraz Rashid, Henry Ford Health System, United States

Reviewed by

Brandon Peter Lucke-Wold, University of Florida, United States

Robert Daniel Nass, University Hospital Bonn, Germany

Updates

Copyright

*Correspondence: Pradeep Kumar, ;

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics